Navigation Links
Researchers discover possible biomarker and therapeutic target for melanoma

(Boston) Researchers at Boston University School of Medicine (BUSM), in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma. The novel cell screening method used in the study also clarifies the process behind tumor metastasis and may allow the identification of biomarkers for other aggressive cancers. The findings now appear online in Cancer Research.

According to the American Cancer Society melanoma is the most serious type of skin cancer and one in 55 people will be diagnosed with it during their lifetime. Previous research has found that metastasis causes more than 90 percent of solid tumor deaths throughout the world and is particularly aggressive in melanoma.

The researchers investigated the process through which melanoma cells communicate with blood vessel cells and promote the formation of tube-like conduits that may allow for tumor metastasis. With the combined expertise of the biologists and biomedical engineers they used microfluidics technology to identify molecules that were essential to this communication process. They found that the molecule Neuropilin-2 played a large role in the process and that silencing it inhibited cancer cell growth.

"We found that Neuropilin is an important mediator of melanoma cell and blood vessel cell interactions," said Rhoda Alani, MD, BUSM professor and Chair of Dermatology. "We can now investigate this molecule as a potential biomarker and melanoma treatment target. We can also use the unique methodology developed in these studies to evaluate cellular crosstalk between other tumor cell types and vessel cells. Such studies are likely to provide important insights into the metastatic process for other cancers."

According to the researchers the cell-to-cell communication process necessary for metastasis of tumors has garnered much attention recently but detailed knowledge of its underlying molecular mechanisms is lacking. These findings clarify this process in melanoma tumors and support the use of the team's methods to discover novel factors controlling cell communication for a variety of malignances.


Contact: Nathan Bliss
Boston University Medical Center

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
Breaking Medicine Technology: